Page last updated: 2024-10-23

atenolol and Hemangioendothelioma

atenolol has been researched along with Hemangioendothelioma in 1 studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yu, L2
Wei, L2
Ma, L2
Li, L2

Other Studies

1 other study available for atenolol and Hemangioendothelioma

ArticleYear
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
    The Journal of dermatology, 2023, Volume: 50, Issue:4

    Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi

2023
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
    The Journal of dermatology, 2023, Volume: 50, Issue:4

    Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi

2023
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
    The Journal of dermatology, 2023, Volume: 50, Issue:4

    Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi

2023
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
    The Journal of dermatology, 2023, Volume: 50, Issue:4

    Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi

2023